Novavax soars on $1.4B deal with Sanofi for COVID vaccine
Sanofi announced a deal worth up to $1.4 billion with Novavax on Friday for its COVID-19 vaccine, giving the Maryland-based biotech a much-needed boost to its struggling business.
If you are not happy with the results below please do another search
Sanofi announced a deal worth up to $1.4 billion with Novavax on Friday for its COVID-19 vaccine, giving the Maryland-based biotech a much-needed boost to its struggling business.
Survey of life sciences experts found 70% recognize potential for AI, but many are struggling to get started or implement it at scale due to challenges including data integrity and interoperability.
IPG Health today announced the next evolution of its unmatched global offering after launching successfully nearly three years ago. Doubling down on the connectivity and interoperability that have powered meteoric growth, the network is further integrating some of its already closely aligned agencies to fuel the next era of innovation and impact.
Takeda saw a 57% drop in profit in its 2023 fiscal year and has lowered its outlook for the coming fiscal year, mostly driven by increasing generic competition for its ADHD treatment Vyvanse.
An autologous and personalized regulatory T cell therapy is safe in patients with type 1 diabetes, but does not help preserve β-cell function.
Drugmaker Viatris narrowly missed first-quarter revenue estimates on Thursday, hurt by weak sales for its older drugs such as cholesterol medication Lipitor and Norvasc for high blood pressure.
Danish drugmaker Novo is trying to expand beyond its blockbuster obesity drug Wegovy with at least eight other treatments in its R&D pipeline for the condition.
The drugmaker’s Keytruda therapy in combination with chemotherapy was being evaluated in about 1,095 patients with high-risk endometrial cancer after surgery.
The recommendation is based on concerns that the company has not sufficiently addressed the problems and risks with the recalled devices.
Sarepta Therapeutics is anticipating full FDA approval and a label expansion for its gene therapy, Elevidys, with the company indicating on its Q1 earnings call last week that a draft label is imminent. But the therapy has come under the microscope regarding its high cost and clinical effectiveness.